A new era of stroke prevention in atrial fibrillation: Comparing a new generation of oral anticoagulants with warfarin

International Archives of Medicine

Volumn 6, Issue 1, 2013, Pages

  Stambler, Bruce S ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Bleeding; Dabigatran; Edoxaban; Hemorrhage; Rivaroxaban; Stroke; Warfarin

Indexed keywords

APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; LIXIANA; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; EFFUSION; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; MONITORING; REVIEW;

EID: 84886738342     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-6-46     Document Type: Review

References (58)

1. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Wolf PA, Abbott RD, Kannel WB, Stroke 1991 22 8 983 988 10.1161/01.STR.22.8.983 1866765
2. Passel JS, D'Vera C, February 11, 2008. U.S. population projections: 2005-2050, Pew Research Center 2008 http://pewhispanic.org/files/reports/85.pdf
3. 2011 ACCF/AHA/HRS focused updated incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, J Am Coll Cardiol 2011 57 11 101 e198 10.1016/j.jacc.2010.09.013 21392637
4. Status of the epidemiology of AF. Kannel WB, Benjamin EJ, Med Clin North Am 2008 92 1 17 40 10.1016/j.mcna.2007.09.002 18060995 (Pubitemid 350182405)
5. Atrial fibrillation is associated with severe acute ischemic stroke. Dulli DA, Stanko H, Levine RL, Neuroepidemiology 2003 22 2 118 123 10.1159/000068743 12629277 (Pubitemid 36302428)
6. Stroke severity in atrial fibrillation. The Framingham Study. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB, Stroke 1996 27 10 1760 1764 10.1161/01.STR.27.10.1760 8841325 (Pubitemid 26332500)
7. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Hughes M, Lip GY, Thromb Haemost 2008 99 2 295 304 18278178 (Pubitemid 351230959)
8. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Stroke Risk in Atrial Fibrillation Working Group, Neurology 2007 69 6 546 554 17679673
9. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ, JAMA 2001 285 22 2864 2870 10.1001/jama.285.22.2864 11401607 (Pubitemid 32537350)
10. Meta-analysis: anticoagulant therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Hart RG, Pearce LA, Aguilar MI, Ann Intern Med 2007 146 12 857 867 10.7326/0003-4819-146-12-200706190-00007 17577005 (Pubitemid 351650486)
11. Barriers to the use of anticoagulation for non-valvular atrial fibrillation (NVAF): a representative survey of Australian family physicians. Gattellari M, Worthington JM, Zwar NA, Middleton S, Stroke 2007 39 1 227 230 18048861
12. Adverse outcomes and predictors of underuse of anticoagulant therapy in Medicare beneficiaries with chronic atrial fibrillation. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ, Stroke 2000 31 4 822 827 10.1161/01.STR.31.4.822 10753982 (Pubitemid 30198422)
13. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, Lemery R, Bahnson TD, Cannom DS, Josephson ME, Zimetbaum P, Am J Cardiol 2006 97 4 538 543 10.1016/j.amjcard.2005.09.086 16461052 (Pubitemid 43190046)
14. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D, Stroke 2001 32 2 392 398 10.1161/01.STR.32.2.392 11157172 (Pubitemid 32155224)
15. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. Baker WL, Cios DA, Sander SD, Coleman CI, J Manag Care Pharm 2009 15 3 244 252 19326955
16. Coumadin® (warfarin sodium) tablets: prescribing information http://packageinserts.bms.com/pi/pi-coumadin.pdf
17. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest Physicians, Chest 2008 133 6 257S 298S 18574268 (Pubitemid 351892969)
18. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS, Ann Intern Med 2009 151 5 297 305 10.7326/0003-4819-151-5-200909010- 00003 19721017
19. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. Hylek EM, Skates SJ, Sheehan MA, Singer DE, N Engl J Med 1996 335 8 540 546 10.1056/NEJM199608223350802 8678931 (Pubitemid 26272308)
20. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Landefeld CS, Goldman L, Am J Med 1989 87 2 144 152 10.1016/S0002-9343(89)80689-8 2787958 (Pubitemid 19201634)
21. A novel user friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY, Chest 2010 138 5 1093 1100 10.1378/chest.10-0134 20299623
22. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Olesen JB, Lip GYH, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C, Thromb Haemost 2011 106 4 739 749 10.1160/TH11-05-0364 21789337
23. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT, Chest 1998 144 5 Suppl 445S 469S (Pubitemid 28535775)
24. New anticoagulant drugs: the Seventh ACCP Conference on Anticoagulants and Thrombolytic Therapy. Weitz JI, Hirsh J, Samama MM, Chest 2004 126 3 Suppl 265S 286S 15383475 (Pubitemid 39297957)
25. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Eriksson BI, Quinlan DJ, Weitz JI, Clin Pharmacokinet 2009 48 1 1 22 10.2165/0003088-200948010-00001 19071881
26. Edoxaban: a new oral direct factor Xa inhibitor. Camm AJ, Bounameaux H, Drugs 2011 71 12 1503 1526 10.2165/11595540-000000000-00000 21861537
27. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A, Thromb Haemost 2010 103 6 1116 1127 10.1160/TH09-11-0758 20352166
28. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D, Drug Metab Dispos 2009 37 5 1056 1064 10.1124/dmd.108.025569 19196845
29. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, Lacreta F, Br J Clin Pharmacol 2013 75 2 476 487 10.1111/j.1365-2125.2012.04369.x 22759198
30. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ, Drug Metab Dispos 2010 38 3 448 458 10.1124/dmd.109.029694 19940026
31. Guidance on the emergent reversal of oral thrombin and factor Xa. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J, Am J Hematol 2012 87 Suppl 1 141 S145 22473649
32. Ridgefield CT, Boehringer Ingelheim Pharmaceuticals, Inc, Pradaxa® (dabigatran etexilate mesylate) capsules: prescribing information 2011 http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf
33. Raritan NJ, Janssen Pharmaceuticals, Inc, Xarelto® (rivaroxaban) tablets prescribing information 2011 http://www.xareltohcp.com/sites/default/ files/pdf/xarelto-0.pdf#zoom=100
34. Princeton NJ, Bristol-Myers Squibb Company, Eliquis® (apixaban) tablets prescribing information 2012 http://packageinserts.bms.com/pi/pi- eliquis.pdf
35. Absolute bioavailability of edoxaban in healthy subjects. Matsushima N, Lee F, Sato T, Weiss D, Mendel J, AAPS J 2011 13 Suppl 2 2362
36. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S, J Clin Pharmacol 2010 50 7 743 753 10.1177/0091270009351883 20081065
37. Drug-drug interaction studies of cardiovascular drugs (amiodarone, digoxin, quinidine, atorvastatin and verapamil) involving p-glycoprotein (P-GP), and efflux transporter, on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban, an oral factor Xa inhibitor. Mendel J, Zahir H, Ridout G, Noveck R, Lee F, Chen S, Zhang G, Shi M, JACC 2011 57 Suppl 1510
38. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. Masumoto H, Yoshigae Y, Watanabe K, Takakusa H, Okazaki O, Izumi T, AAPS J 2010 12 Suppl 2 4308
39. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J, Drug Metab Dispos 2012 40 12 2250 2255 10.1124/dmd.112.046888 22936313
40. European Medicines Agency, CHMP Assessment Report for Xarelto http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/000944/WC500057122.pdf
41. Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators, N Engl J Med 2009 361 12 1139 1151 10.1056/NEJMoa0905561 19717844
42. Management of bleeding complications in the anticoagulated patient. Bhagirath VC, O'Malley L, Crowther MA, Semin Hematol 2011 48 4 285 294 10.1053/j.seminhematol.2011.08.008 22000094
43. Effect of activated charcoal on the pharmacokinetics of apixaban in healthy subjects. Wang X, Tirucherai G, Pannacciulli N, Wang J, Elsrougy A, Teslenko V, Chang M, Zhang D, Frost C, Clin Pharmacol Ther 2012 91 Suppl 1 41
44. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A, Blood 2009 114 22 1065
45. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G, Clin Pharmacol Ther 2005 78 4 412 421 10.1016/j.clpt.2005.06.011 16198660 (Pubitemid 41393676)
46. Reversal of new oral anticoagulants. Battinelli EM, Circulation 2011 124 14 1508 1510 10.1161/CIRCULATIONAHA.111.054510 21969317
47. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Chang M, Yu Z, Shenker A, Wang J, Pursley J, Boyd R, LaCreta F, Frost C, Clin Pharmacol Drug Dev 2012 1 4 185 186
48. Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Wang X, Song Y, Tirucherai G, Ehlgen A, Wang J, Chang M, Zhang D, Frost C, Clin Pharmacol Drug Dev 2012 1 4 187
49. Apixaban versus warfarin in patients with atrial fibrillation. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al. N Engl J Med 2011 365 11 981 992 10.1056/NEJMoa1107039 21870978
50. Apixaban in patients with atrial fibrillation. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee and Investigators, N Engl J Med 2011 364 9 806 817 10.1056/NEJMoa1007432 21309657
51. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E, Am Heart J 2010 160 4 635 641 10.1016/j.ahj.2010.06.042 20934556
52. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators, N Engl J Med 2011 365 10 883 891 10.1056/NEJMoa1009638 21830957
53. Newly identified events in the RE-LY trial. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, N Engl J Med 2010 363 19 1875 1876 10.1056/NEJMc1007378 21047252
54. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S, Stroke 2012 43 6 1511 1517 10.1161/STROKEAHA.112.650614 22492518
55. Dabigatran etexilate mesylate capsules: Advisory Committee Briefing Document 2010 http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM226009.pdf
56. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, Hylek E, Ansell JE, Wallentin L, Eur Heart J 2012 33 685 686
57. Pradaxa® (dabigatran etexilate mesylate), Drug safety communication-safety review of post-market reports of serious bleeding events 2011 http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm282820.htm
58. Dabigatran versus warfarin in patients with mechanical heart valves. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, RE-ALIGN Investigators, N Engl J Med 2013 369 13 1206 1214 10.1056/NEJMoa1300615 23991661